FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311579551> ?p ?o ?g. }

• W4311579551 abstract "This phase 2 study assesses the efficacy and safety of camrelizumab (an anti-PD-1 antibody) plus famitinib (anti-angiogenic agent) in women with pretreated recurrent or metastatic cervical cancer (ClinicalTrials.gov NCT03827837). Patients with histologically or cytologically confirmed cervical squamous cell carcinoma experiencing relapse or progression during or after 1-2 lines of systemic therapy for recurrent or metastatic disease are enrolled. Eligible patients receive camrelizumab 200 mg intravenously on day 1 of each 3-week cycle plus famitinib 20 mg orally once daily. The primary endpoint is the objective response rate. Secondary endpoints are duration of response, disease control rate, time to response, progression-free survival, overall survival, and safety. The trial has met pre-specified endpoint. Thirty-three patients are enrolled; median follow-up lasts for 13.6 months (interquartile range: 10.0-23.6). Objective responses are observed in 13 (39.4%, 95% confidence interval [CI]: 22.9-57.9) patients; the 12-month duration of response rate is 74.1% (95% CI: 39.1-90.9). Median progression-free survival is 10.3 months (95% CI: 3.5-not reached) and the 12-month overall survival rate is 77.7% (95% CI: 58.9-88.7). All patients experience treatment-related adverse events; grade ≥3 events occur in 26 (78.8%) patients. Treatment-related serious adverse events and deaths are observed in 9 (27.3%) and 2 (6.1%) patients, respectively. Camrelizumab plus famitinib shows promising antitumor activity with a manageable and tolerable safety profile in patients with pretreated recurrent or metastatic cervical squamous cell carcinoma. This combination may represent a treatment option for this population." @default.
• W4311579551 created "2022-12-27" @default.
• W4311579551 creator A5003910917 @default.
• W4311579551 creator A5017078761 @default.
• W4311579551 creator A5023021675 @default.
• W4311579551 creator A5025062638 @default.
• W4311579551 creator A5030056860 @default.
• W4311579551 creator A5064779408 @default.
• W4311579551 creator A5074481742 @default.
• W4311579551 creator A5083540772 @default.
• W4311579551 creator A5088829354 @default.
• W4311579551 creator A5089296993 @default.
• W4311579551 creator A5089728453 @default.
• W4311579551 date "2022-12-08" @default.
• W4311579551 modified "2023-09-30" @default.
• W4311579551 title "A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma" @default.
• W4311579551 cites W1869230314 @default.
• W4311579551 cites W1983763042 @default.
• W4311579551 cites W2064196121 @default.
• W4311579551 cites W2092241508 @default.
• W4311579551 cites W2100756525 @default.
• W4311579551 cites W2170825221 @default.
• W4311579551 cites W2318880831 @default.
• W4311579551 cites W2342029300 @default.
• W4311579551 cites W2569537049 @default.
• W4311579551 cites W2742133220 @default.
• W4311579551 cites W2791328450 @default.
• W4311579551 cites W2890100090 @default.
• W4311579551 cites W2925815206 @default.
• W4311579551 cites W2968968778 @default.
• W4311579551 cites W2972117663 @default.
• W4311579551 cites W2977790547 @default.
• W4311579551 cites W3008514541 @default.
• W4311579551 cites W3025003676 @default.
• W4311579551 cites W3026296708 @default.
• W4311579551 cites W3032571309 @default.
• W4311579551 cites W3089334084 @default.
• W4311579551 cites W3091040812 @default.
• W4311579551 cites W3093964219 @default.
• W4311579551 cites W3108850818 @default.
• W4311579551 cites W3111665711 @default.
• W4311579551 cites W3128646645 @default.
• W4311579551 cites W3135689597 @default.
• W4311579551 cites W3155156689 @default.
• W4311579551 cites W3194142087 @default.
• W4311579551 cites W3200109370 @default.
• W4311579551 cites W3200231835 @default.
• W4311579551 cites W4206587934 @default.
• W4311579551 cites W4212784899 @default.
• W4311579551 cites W4213066621 @default.
• W4311579551 cites W4226407945 @default.
• W4311579551 cites W4280534053 @default.
• W4311579551 cites W4297769674 @default.
• W4311579551 doi "https://doi.org/10.1038/s41467-022-35133-4" @default.
• W4311579551 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36481736" @default.
• W4311579551 hasPublicationYear "2022" @default.
• W4311579551 type Work @default.
• W4311579551 citedByCount "3" @default.
• W4311579551 countsByYear W43115795512023 @default.
• W4311579551 crossrefType "journal-article" @default.
• W4311579551 hasAuthorship W4311579551A5003910917 @default.
• W4311579551 hasAuthorship W4311579551A5017078761 @default.
• W4311579551 hasAuthorship W4311579551A5023021675 @default.
• W4311579551 hasAuthorship W4311579551A5025062638 @default.
• W4311579551 hasAuthorship W4311579551A5030056860 @default.
• W4311579551 hasAuthorship W4311579551A5064779408 @default.
• W4311579551 hasAuthorship W4311579551A5074481742 @default.
• W4311579551 hasAuthorship W4311579551A5083540772 @default.
• W4311579551 hasAuthorship W4311579551A5088829354 @default.
• W4311579551 hasAuthorship W4311579551A5089296993 @default.
• W4311579551 hasAuthorship W4311579551A5089728453 @default.
• W4311579551 hasBestOaLocation W43115795511 @default.
• W4311579551 hasConcept C119060515 @default.
• W4311579551 hasConcept C121608353 @default.
• W4311579551 hasConcept C126322002 @default.
• W4311579551 hasConcept C141071460 @default.
• W4311579551 hasConcept C143998085 @default.
• W4311579551 hasConcept C197934379 @default.
• W4311579551 hasConcept C203092338 @default.
• W4311579551 hasConcept C2776694085 @default.
• W4311579551 hasConcept C2778220009 @default.
• W4311579551 hasConcept C2779984678 @default.
• W4311579551 hasConcept C2780739268 @default.
• W4311579551 hasConcept C31760486 @default.
• W4311579551 hasConcept C44249647 @default.
• W4311579551 hasConcept C535046627 @default.
• W4311579551 hasConcept C71924100 @default.
• W4311579551 hasConceptScore W4311579551C119060515 @default.
• W4311579551 hasConceptScore W4311579551C121608353 @default.
• W4311579551 hasConceptScore W4311579551C126322002 @default.
• W4311579551 hasConceptScore W4311579551C141071460 @default.
• W4311579551 hasConceptScore W4311579551C143998085 @default.
• W4311579551 hasConceptScore W4311579551C197934379 @default.
• W4311579551 hasConceptScore W4311579551C203092338 @default.
• W4311579551 hasConceptScore W4311579551C2776694085 @default.
• W4311579551 hasConceptScore W4311579551C2778220009 @default.
• W4311579551 hasConceptScore W4311579551C2779984678 @default.
• W4311579551 hasConceptScore W4311579551C2780739268 @default.
• W4311579551 hasConceptScore W4311579551C31760486 @default.
• W4311579551 hasConceptScore W4311579551C44249647 @default.

• next